These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 30548485)

  • 1. Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.
    Calip GS; Moran KM; Sweiss KI; Patel PR; Wu Z; Adimadhyam S; Lee TA; Ko NY; Quigley JG; Chiu BC
    Cancer; 2019 Apr; 125(7):1143-1154. PubMed ID: 30548485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer.
    Calip GS; Malmgren JA; Lee WJ; Schwartz SM; Kaplan HG
    Breast Cancer Res Treat; 2015 Nov; 154(1):133-43. PubMed ID: 26450505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma.
    Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
    Cancer; 2010 Nov; 116(22):5279-89. PubMed ID: 20665502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience.
    Cerchione C; De Renzo A; Di Perna M; Della Pepa R; Pugliese N; Catalano L; Pane F; Picardi M
    Support Care Cancer; 2017 Mar; 25(3):839-845. PubMed ID: 27812763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
    Salmon JP; Smakal M; Karanikiotis C; Wojtukiewicz MZ; Omnes Y; DeCosta L; Wetten S; O'Kelly J
    Support Care Cancer; 2019 Apr; 27(4):1449-1457. PubMed ID: 30259136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy.
    Schenfeld J; Gong T; Henry D; Kelsh M; Gawade P; Peng Y; Bradbury BD; Li S
    Support Care Cancer; 2022 Jul; 30(7):6327-6338. PubMed ID: 35482126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Granulocyte Colony-Stimulating Factor (G-CSF) Use and Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Among Elderly Patients with Breast, Lung, or Prostate Cancer.
    Danese MD; Schenfeld J; Shaw J; Gawade P; Balasubramanian A; Kelsh M; Hernandez RK; Lyman G
    Adv Ther; 2022 Jun; 39(6):2778-2795. PubMed ID: 35430673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
    Griffiths RI; Barron RL; Gleeson ML; Danese MD; O'Hagan A; Chia VM; Legg JC; Lyman GH
    Pharmacoeconomics; 2012 Feb; 30(2):103-18. PubMed ID: 21967155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
    Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.
    Kang KW; Lee BH; Jeon MJ; Yu ES; Kim DS; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS
    Cancer Med; 2020 Sep; 9(17):6102-6110. PubMed ID: 32633471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
    Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy.
    Lyman GH; Reiner M; Morrow PK; Crawford J
    Ann Oncol; 2015 Jul; 26(7):1452-8. PubMed ID: 25851633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF).
    Naeim A; Henk HJ; Becker L; Chia V; Badre S; Li X; Deeter R
    BMC Cancer; 2013 Jan; 13():11. PubMed ID: 23298389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis.
    Cooper KL; Madan J; Whyte S; Stevenson MD; Akehurst RL
    BMC Cancer; 2011 Sep; 11():404. PubMed ID: 21943360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis.
    Lee S; Knox A; Zeng IS; Coomarasamy C; Blacklock H; Issa S
    Support Care Cancer; 2013 Mar; 21(3):841-6. PubMed ID: 22972488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study.
    Link H; Illerhaus G; Martens UM; Salar A; Depenbusch R; Köhler A; Engelhardt M; Mahlmann S; Zaiss M; Lammerich A; Bias P; Buchner A
    Support Care Cancer; 2021 May; 29(5):2519-2527. PubMed ID: 32944800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study.
    Weycker D; Doroff R; Hanau A; Bowers C; Belani R; Chandler D; Lonshteyn A; Bensink M; Lyman GH
    BMC Cancer; 2019 Aug; 19(1):792. PubMed ID: 31399079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2).
    Yokoyama M; Kusano Y; Nishihara A; Inoue N; Nishimura N; Mishima Y; Terui Y; Nukada T; Nomura T; Hatake K
    Support Care Cancer; 2020 Feb; 28(2):571-579. PubMed ID: 31093770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
    Wang L; Baser O; Kutikova L; Page JH; Barron R
    Support Care Cancer; 2015 Nov; 23(11):3131-40. PubMed ID: 25821144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.